Market Overview

UPDATE: Citigroup Reiterates Neutral Rating, Raises PT on Allscripts Healthcare Solutions

Share:
Related MDRX
Benzinga's Top Upgrades
Jefferies: 10 Buyout Targets To Own During The M&A Boom
Recent IPO Medical Transcription Billing Looks Like A Value Play With Growth Opportunities (Seeking Alpha)

In a report published Wednesday, Citigroup reiterated its Neutral rating on Allscripts Healthcare Solutions (NASDAQ: MDRX), and slightly raised its price target from $10.50 to $11.00.

Citigroup noted, “We believe Allscripts faces significant challenges on the product development and sales execution fronts, but many of these challenges are priced into the stock. We are modestly raising our 2012 and 2013 EPS estimates on the company's recent aggressive repurchase of shares. We are not yet ready to get more positive on the shares, but could be in a position to do so if we believe the company can fix its operational issues and restore faith to its customer base.”

Allscripts Healthcare Solutions closed Tuesday at $9.79.

Latest Ratings for MDRX

DateFirmActionFromTo
Apr 2015Piper JaffrayUpgradesUnderweightNeutral
Apr 2015Stifel NicolausInitiates Coverage onHold
Mar 2015RW BairdInitiates Coverage onOutperform

View More Analyst Ratings for MDRX
View the Latest Analyst Ratings

Posted-In: CitigroupAnalyst Color Price Target Analyst Ratings

 

Related Articles (MDRX)

Around the Web, We're Loving...

Get Benzinga's Newsletters